|
APONTIS PHARMA AG / Key word(s): Forecast/Change in Forecast APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications 05-Apr-2024 / 10:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications Monheim / Rhein, 5 April 2024. APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5) has entered into a five-year agreement with Novartis Pharma GmbH to take over the distribution and marketing of two medications in the asthma indication for Germany. The Company expects a sales contribution of around EUR 9 million and an earnings contribution of up to EUR 1.5 million for the 2024 financial year. APONTIS PHARMA is therefore raising its forecast for 2024 and now expects an increase in sales to EUR 50.7 million (previously: EUR 41.7 million) and a positive EBITDA of EUR 3.3 million (previously: positive EBITDA of EUR 1.8 million). APONTIS PHARMA AG Investor Relations APONTIS PHARMA press contact CROSS ALLIANCE communication GmbH End of Inside Information 05-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Amicus briefs fly in as IRA ‘fair price’ deadline looms
Amicus briefs are piling up in support of drug price negotiations under the Inflation Reduction Act ahead of a key February deadline by which the
January 17, 2024